Judge throws out Merck’s $200 million verdict over Gilead

A federal judge has reversed a jury’s verdict that Gilead Sciences Inc. should pay $200 million to Merck & Co. in a drug-patent dispute, after the judge concluded Merck engaged in misconduct in its efforts to obtain patents for hepatitis C drugs.